通过天眼查大数据分析，四川金石亚洲医药股份有限公司共对外投资了7家企业，参与招投标项目2次， 知识产权方面有商标信息13条，专利信息45条，此外企业还拥有行政许可20个。 来源：金融界 金石亚药最新一期业绩显示，截至2025一季报，公司营业总收入2.91亿元、同比减少19.65%，归属净利 润6285.13万元，同比减少30.02%，扣非净利润5773.03万元，同比减少34.13%，流动比率2.547、速动比 率1.981、资产负债率15.08%。 天眼查商业履历信息显示，四川金石亚洲医药股份有限公司，成立于2004年，位于成都市，是一家以从 事医药制造业为主的企业。企业注册资本40174.3872万人民币，实缴资本40174万人民币。公司法定代 表人为马益平。 金融界消息 截至2025年7月29日收盘，金石亚药（300434）报收于10.9元，上涨3.22%，换手率 11.28%，成交量38.60万手，成交金额4.16亿元。 资金流向方面，今日主力资金净流入3457.87万元，占比成交额8.31%。其中，超大单净流入201.84万 元、占成交额0.48%，大单净流入3256.04万元、占成交额7.82%， ...

证券代码：300434 证券简称：金石亚药 公告编号：2025-030 四川金石亚洲医药股份有限公司 关于董事兼高级管理人员股份减持计划实施完成的公告 近日，公司收到林强先生出具的《关于股份减持计划实施完毕的告知函》， 本次减持计划已实施完毕。现将有关情况公告如下： 公司董事、副总裁、董事会秘书林强先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 减持占总股本 | | --- | --- | --- | --- | --- | --- | | | | | （元/股） | （股） | 比例 | | 林强 | 集中竞价 | 2025年7月15 | 10.40 | 676,200 | 0.17% | | | 大宗交易 | 日至7月24日 | 10.78 | 860,000 | 0.21% | | | | 合计 | | 1,536,200 | 0.38% | 一、股份减持完成情况 注：1、上述股东减持股份来源为首次公开发行股票前持有的股份以及该等股份上市后资本 公积金转增股本取得的股份。 2、计算占比时，按 ...

Core Viewpoint - The company has not yet established a partnership with the electricity company in the Tibet region [1] Group 1: Company Developments - The company is focused on enhancing the technology of plastic composite pipes and vacuum coating technology [1] - The company leads in technology for municipal water supply and drainage composite pipes, flexible composite pipes for the oil and gas industry, and magnetron sputtering vacuum coating [1] - The company is actively expanding its domestic and international markets, achieving product exports to multiple countries [1]

类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：盛晓霞 一、基本情况 四川金石亚洲医药股份有限公司（以下简称"公司"）于2025年7月4日召开第 五届董事会第九次会议，审议通过了《关于向全资子公司浙江亚克药业增资的议 案》。公司全资一级子公司海南亚洲制药股份有限公司（以下简称"亚洲制药"） 以自有资金人民币2亿元向公司全资二级子公司浙江亚克药业有限公司（以下简称 "亚克药业"）增资。本次增资完成后，亚克药业的注册资本由人民币1.5亿元增 加至3.5亿元。具体内容详见2025年7月5日在巨潮资讯网披露的《关于向全资子公 司增资的公告》（公告编号：2025-025）。 近日，亚克药业已完成相关工商变更登记手续，取得了杭州高新技术产业开发 区（滨江）市场监督管理局换发的《营业执照》。 二、新取得营业执照基本信息 名称：浙江亚克药业有限公司 统一社会信用代码：913301087042191902 证券代码：300434 证券简称：金石亚药 公告编号：2025-029 四川金石亚洲医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注册资本： ...

证券代码：300434 证券简称：金石亚药 公告编号：2025-029 统一社会信用代码：913301087042191902 类型：有限责任公司（自然人投资或控股的法人独资） 法定代表人：盛晓霞 四川金石亚洲医药股份有限公司 关于全资子公司增资事项进展暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 四川金石亚洲医药股份有限公司（以下简称"公司"）于2025年7月4日召开第 五届董事会第九次会议，审议通过了《关于向全资子公司浙江亚克药业增资的议 案》。公司全资一级子公司海南亚洲制药股份有限公司（以下简称"亚洲制药"） 以自有资金人民币2亿元向公司全资二级子公司浙江亚克药业有限公司（以下简称 "亚克药业"）增资。本次增资完成后，亚克药业的注册资本由人民币1.5亿元增 加至3.5亿元。具体内容详见2025年7月5日在巨潮资讯网披露的《关于向全资子公 司增资的公告》（公告编号：2025-025）。 近日，亚克药业已完成相关工商变更登记手续，取得了杭州高新技术产业开发 区（滨江）市场监督管理局换发的《营业执照》。 二、新取得营业 ...

Group 1 - The innovative drug sector remains active, with companies such as Wanbangde (002082) and Hasanlian (002900) seeing significant market activity in the afternoon session [1] - Other companies like Lizhu Group (000513), Jiankangyuan (600380), and Jinshiyao (300434) are also experiencing upward movement in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and market dynamics [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-028 四川金石亚洲医药股份有限公司 关于子公司参与集中带量采购拟中选的公告 本公司及董事会全体成员、保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，四川金石亚洲医药股份有限公司（以下简称"公司"）全资二级子公 司浙江迪耳药业有限公司（以下简称"迪耳药业"）参与了新疆维吾尔自治区二 十六省联盟药品集中带量采购工作。根据新疆维吾尔自治区医疗保障局发布的《二 十六省联盟药品集中带量采购综合评审拟中选结果表》显示，迪耳药业的制霉素 阴道栓产品拟中选本次集中带量采购，现将相关中选情况公告如下： 注：1、根据新疆维吾尔自治区医疗保障局发布的《二十六省联盟药品集中带 量采购文件》（编号 XJYPDL2025-1）要求：本次集中采购周期自中选结果执行之 日起至 2027 年 12 月 31 日。 公司拟中选产品相关采购协议尚未签订，后续事项及对公司的影响程度尚具 有不确定性。敬请广大投资者谨慎决策，注意投资风险。 特此公告。 四川金石亚洲医药股份有限公司 2、本次拟中选区域为新疆、北京、天津、山西、内蒙古等二十六省（自治区、 ...

Sichuan Jinshi Asia Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast [Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates substantial H1 2025 performance growth, with net profit attributable to shareholders increasing by 50.04% to 85.24% and non-recurring adjusted net profit by 31.28% to 68.55% 2025 Semi-Annual Performance Forecast Key Data | Metric | Current Period (2025 H1 Est.) | Prior Period (2024 H1) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Million Yuan) | 58.82 - 72.62 | 39.20 | 50.04% - 85.24% | | Net Profit After Non-Recurring Items (Million Yuan) | 48.62 - 62.42 | 37.04 | 31.28% - 68.55% | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company explicitly states that the financial data presented in this performance forecast remains unaudited by an accounting firm - The data in this performance forecast is unaudited by an accounting firm[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Performance growth is attributed to optimized budget and cost control, successful commercialization of new materials and machinery R&D projects, and a positive impact from non-recurring gains and losses - The company achieved a reduction in period expenses through measures such as budget optimization and cost control, fostering stable business development[4](index=4&type=chunk) - The new materials and machinery business segment saw improved revenue and gross profit due to the commercialization of certain prior R&D projects[4](index=4&type=chunk) - During the reporting period, non-recurring gains and losses are estimated to have a positive impact of approximately **10.19 million yuan** on net profit[4](index=4&type=chunk) [Other Relevant Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) This performance forecast represents preliminary financial department estimates, with final accurate data to be disclosed in the 2025 semi-annual report, cautioning investors about associated risks - This performance forecast is a preliminary estimate by the company's finance department, with specific financial data subject to the 2025 semi-annual report[5](index=5&type=chunk) [Reference Documents](index=2&type=section&id=%E4%BA%94%E3%80%81%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6) The board of directors' explanation regarding the 2025 semi-annual performance forecast is designated as a reference document in the announcement - The reference document is the board of directors' explanation regarding the 2025 semi-annual performance forecast[6](index=6&type=chunk)

金石亚药（300434）公告，预计2025年上半年净利润为5881.72万元-7261.78万元，比上年同期的 3920.22万元增长50.04%-85.24%。 ...

Core Insights - Sichuan Jinshi Yao Pharmaceutical Co., Ltd. has made significant progress in its strategic layout in the dermatological drug sector by launching the first commercialized dexamethasone ointment in China under its children's drug brand "Xiaokuai Ke" in collaboration with the innovative dermatological drug brand "Shushining" [1] - The dexamethasone ointment adheres to the principle of "simplicity equals safety," containing only the active ingredient dexamethasone and the base white vaseline, eliminating potential allergens such as preservatives, emulsifiers, and fragrances, addressing the core pain points of pediatric medication safety [1] Market Opportunity - At present, atopic dermatitis (AD) has become a core challenge in health management for Chinese families, with a patient base of 70.7 million in 2022, nearly half of whom are children and adolescents [2] - The market for AD is projected to grow at a compound annual growth rate (CAGR) of 18.6%, expected to exceed 30.5 billion yuan by 2030, with the children's segment anticipated to surpass 4.5 billion yuan [3] Product Innovation - The dexamethasone ointment is the only approved formulation of its kind in China, featuring an oil-based matrix that enhances penetration and reduces stickiness compared to traditional creams and ointments, significantly improving barrier repair efficiency [5] - The product's formulation, which includes only dexamethasone and white vaseline, minimizes skin irritation and damage, aligning with the WHO's recommendations for pediatric use of topical corticosteroids [4][5] Strategic Positioning - The launch of the dexamethasone ointment represents a strategic move for Jinshi Yao, enhancing its product matrix in the children's dermatological drug market and solidifying its brand position in the pediatric pharmaceutical sector [6][8] - The company has established six core health product lines, with the dexamethasone ointment serving as the first specialized pediatric dermatological drug, contributing to a comprehensive health ecosystem that addresses various life stages and health management needs [7][8] Long-term Vision - Jinshi Yao aims to build a sustainable health ecosystem, with the launch of the dexamethasone ointment being a critical piece of its dermatological strategy, reflecting a commitment to long-term growth and investment value [6][9] - The company's mission to "provide good medicine and serve society" aligns with national health strategies, particularly in safeguarding children's health, thereby enhancing its social responsibility and market position [10][11]